Abstract: The present invention relates to a composition comprising orlistat and acarbose for use in reducing rebound effect in obese or overweight subjects.
Type:
Application
Filed:
May 20, 2022
Publication date:
April 24, 2025
Applicant:
Empros Pharma AB
Inventors:
Jan Stefan Persson GRUDÉN, Anders FORSLUND, Ulf HOLMBÄCK, Jan Arvid SÖDERHALL, Göran ALDERBORN
Abstract: The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns: a) a first part, G1, comprising from about 5 to about 70% w/w of the total dose of acarbose, b) a second part, G2A, comprising from about 30 to about 95% w/w of the total dose of acarbose, c) a third part, G2B, comprising from about 10 to about 90% w/w of the total dose of orlistat, and d) a fourth part, G3, comprising from about 10 to about 80% w/w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w/w.
Type:
Application
Filed:
April 10, 2024
Publication date:
October 17, 2024
Applicant:
EMPROS PHARMA AB
Inventors:
Göran Alderborn, Anders Forslund, Ulf Holmbäck, Hans Lennernäs, Jan Stefan Persson Grudén
Abstract: The invention relates to a composition of orlistat and acarbose for use in improving quality of life. The combination is administered orally to obtain a synergistic effect. The synergistic effect is obtained after 13 weeks or more such a after 14 weeks or more. after 15 weeks or more. after 16 weeks or more. after 17 weeks or more. after 18 weeks or more. after 19 weeks or more. after 20 weeks or more. after 21 weeks or more. after 22 weeks or more. after 23 weeks or more. after 24 weeks or more. after 25 weeks or more of after 26 weeks or more of treatment. The synergistic effect gives improved weight loss.
Type:
Application
Filed:
May 20, 2022
Publication date:
July 11, 2024
Applicant:
Empros Pharma AB
Inventors:
Jan Stefan Persson GRUDÉN, Anders FORSLUND, Ulf HOLMBÄCK, Jan Arvid SÖDERHALL, Göran ALDERBORN
Abstract: The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns: a) a first part, G1, comprising from about 5 to about 70% w/w of the total dose of acarbose, b) a second part, G2A, comprising from about 30 to about 95% w/w of the total dose of acarbose, c) a third part, G2B, comprising from about 10 to about 90% w/w of the total dose of orlistat, and d) a fourth part, G3, comprising from about 10 to about 80% w/w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w/w.
Type:
Grant
Filed:
January 24, 2020
Date of Patent:
May 7, 2024
Assignee:
EMPROS PHARMA AB
Inventors:
Göran Alderborn, Anders Forslund, Ulf Holmbäck, Hans Lennernäs, Jan Stefan Persson Grudén
Abstract: The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns: a) a first part, G1, comprising from about 5 to about 70% w/w of the total dose of acarbose, b) a second part, G2A, comprising from about 30 to about 95% w/w of the total dose of acarbose, c) a third part, G2B, comprising from about 10 to about 90% w/w of the total dose of orlistat, and d) a fourth part, G3, comprising from about 10 to about 80% w/w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w/w.
Type:
Application
Filed:
January 24, 2020
Publication date:
July 23, 2020
Applicant:
EMPROS PHARMA AB
Inventors:
Göran Alderborn, Anders Forslund, Ulf Holmbäck, Hans Lennernäs, Jan Stefan Persson Grudén
Abstract: The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns: a) a first part, G1, comprising from about 5 to about 70% w/w of the total dose of acarbose, b) a second part, G2A, comprising from about 30 to about 95% w/w of the total dose of acarbose, c) a third part, G2B, comprising from about 10 to about 90% w/w of the total dose of orlistat, and d) a fourth part, G3, comprising from about 10 to about 80% w/w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w/w.
Type:
Grant
Filed:
December 17, 2015
Date of Patent:
February 18, 2020
Assignee:
EMPROS PHARMA AB
Inventors:
Göran Alderborn, Anders Forslund, Ulf Holmbäck, Hans Lennernäs, Jan Stefan Persson Grudén
Abstract: The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns: a) a first part, G1, comprising from about 5 to about 70% w/w of the total dose of acarbose, b) a second part, G2A, comprising from about 30 to about 95% w/w of the total dose of acarbose, c) a third part, G2B, comprising from about 10 to about 90% w/w of the total dose of orlistat, and d) a fourth part, G3, comprising from about 10 to about 80% w/w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w/w.
Type:
Application
Filed:
December 17, 2015
Publication date:
December 21, 2017
Applicant:
EMPROS PHARMA AB
Inventors:
Göran Alderborn, Anders Forslund, Ulf Holmbäck, Hans Lennernäs, Jan Stefan Persson Grudén